Advertisement

Supportive Therapie in der geriatrischen Onkologie

  • Hartmut Link
Chapter
Part of the Springer Reference Medizin book series (SRM)

Zusammenfassung

Die Supportivtherapie ist essentieller Bestandteil der onkologischen Therapie und muss insbesondere bei Patienten mit Komorbidität und älteren Patienten gleichermaßen gewertet und beachtet werden. Die Toxizität der Therapieverfahren ist höher, so dass die supportive Therapie früher und intensiver erfolgt als bei den sonstigen Patienten, bei denen auch häufig die Studien zur Supportivtherapie durchgeführt wurden. Im Krankheitsverlauf tritt häufig die Supportivtherapie immer mehr in den Vordergrund des Behandlungskonzeptes.

Literatur

  1. Aapro M, Crawford J, Kamioner D (2010) Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now? Support Care Cancer 18:529–541CrossRefPubMedPubMedCentralGoogle Scholar
  2. Averbuch D, Orasch C, Cordonnier C et al (2013) European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: summary of the 2011 4th European Conference on Infections in Leukemia. Haematologica 98:1826–1835CrossRefPubMedPubMedCentralGoogle Scholar
  3. Bundesärztekammer WBD (2014) Querschnitts-Leitlinien (BÄK) zur Therapie mit Blutkomponenten und Plasmaderivaten, 4., überarb. u. aktual. Aufl. 2014. In: Bundesärztekammer (Hrsg) Bundesärztekammer, S 1–392Google Scholar
  4. Crawford J, Kreisman H, Garewal H et al (1997) The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. Ann Oncol 8:1117–1124CrossRefPubMedGoogle Scholar
  5. Freifeld AG, Bow EJ, Sepkowitz KA et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52:e56–e93CrossRefPubMedGoogle Scholar
  6. Heinz W, Buchheidt D, Christopeit M, et al. Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 2017; im DruckGoogle Scholar
  7. Hellstrom-Lindberg E, Negrin R, Stein R et al (1997) Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99:344–351CrossRefPubMedGoogle Scholar
  8. Hesketh PJ, Kris MG, Basch E et al (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.  https://doi.org/10.1200/JCO.2017.74.4789Google Scholar
  9. Hofmann WK, Platzbecker U, Götze K et al (2016) Myelodysplastische Syndrome (MDS). In: Onkologie DDGfHuM (Hrsg) Onkopedia. DGHO Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie. Berlin. https://www.onkopedia.com/de/onkopedia/guidelines/myelodysplastische-syndrome-mds/@@view/html/index.html
  10. Jadersten M, Malcovati L, Dybedal I et al (2008) Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 26:3607–3613CrossRefPubMedGoogle Scholar
  11. Jordan K, Jahn F, Aapro M (2015) Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 26:1081–1090CrossRefPubMedGoogle Scholar
  12. Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051CrossRefPubMedGoogle Scholar
  13. Klastersky J, De Naurois J, Rolston K et al (2016) Management of febrile neutropaenia: ESMO clinical practice guidelines. Ann Oncol 27:v111–v118CrossRefPubMedGoogle Scholar
  14. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258–2266CrossRefPubMedGoogle Scholar
  15. Leitlinienprogramm Onkologie Deutsche Krebsgesellschaft DK, Awmf (2016) S3-Leitlinie Supportive Therapie bei onkologischen PatientInnenGoogle Scholar
  16. Littlewood TJ, Bajetta E, Nortier JW et al (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19:2865–2874CrossRefPubMedGoogle Scholar
  17. Ludwig H, Van BS, Barrett-Lee P et al (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293–2306CrossRefPubMedGoogle Scholar
  18. Ludwig H, Muldur E, Endler G et al (2013) Prevalence of iron deficiency across different tumors and its association with poor performance status, disease status and anemia. Ann Oncol 24:1886–1892CrossRefPubMedPubMedCentralGoogle Scholar
  19. Ludwig H, Evstatiev R, Kornek G et al (2015) Iron metabolism and iron supplementation in cancer patients. 2015. Wien Klin Wochenschr. 127:907–919Google Scholar
  20. Lyman GH, Michels SL, Reynolds MW et al (2010) Risk of mortality in patients with cancer who experience febrile neutropenia. Cancer 116:5555–5563CrossRefPubMedGoogle Scholar
  21. Lyman GH, Abella E, Pettengell R (2014) Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol 90:190–199CrossRefPubMedGoogle Scholar
  22. Margulies A, Kroner T, Gaisser A et al (2017) Onkologische Krankenpflege. Springer, BerlinGoogle Scholar
  23. Miller CB, Jones RJ, Piantadosi S et al (1990) Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 322:1689–1692CrossRefPubMedGoogle Scholar
  24. Navari RM, Aapro M (2016) Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med 374:1356–1367CrossRefPubMedGoogle Scholar
  25. NCCN (2016) Myeloid Growth Factors. In: National Comprehensive Cancer Network; NCCN® Practice guidelines in oncology – v.2.2016. NCCNGoogle Scholar
  26. Organization DONFA DNWH (2011) Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. In: WHO (Hrsg) VMNIS, Vitamin and mineral nutrition information system. WHO, GenevaGoogle Scholar
  27. Roila F, Herrstedt J, Aapro M et al (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21:v232–v243CrossRefPubMedGoogle Scholar
  28. Roila F, Molassiotis A, Herrstedt J et al (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119–v133CrossRefPubMedGoogle Scholar
  29. Smith TJ, Bohlke K, Lyman GH et al (2015) Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update. J Clin Oncol 33:3199–3212CrossRefPubMedGoogle Scholar
  30. Witzig TE, Silberstein PT, Loprinzi CL et al (2005) Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 23:2606–2617CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.Praxis Hämatologie, internistische OnkologieKaiserslauternDeutschland

Section editors and affiliations

  • Matthias Ebert
    • 1
  1. 1.II. Medizinische KlinikUniversitätsmedizin MannheimMannheimDeutschland

Personalised recommendations